The first North American patient has been treated in StemCells, Inc.‘s Phase I/II clinical trial in chronic spinal cord injury. A team at the University of Calgary successfully transplanted its first subject with the company’s proprietary HuCNS-SC human neural stem cells. The patient is the ninth subject to enroll in the trial, which was initiated in Switzerland.   This expansion from a single-site, single-country study to a multi-site, multi-country program accelerates the curre...